- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03160794
Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy
Phase II Study: [18F]DCFPyL PET/MRI for Personalizing Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (MRgRT)
In the clinical scenario of recurrent prostate cancer (PCa) post local therapy, current standard studies (bone scan and computed tomography) commonly fail to identify the recurrent disease location. In this study the investigator aims to prospectively map recurrent disease with the unique combination of whole-body MR anatomical imaging combined with a new high-sensitivity and PCa-specific PET probe (PSMA-targeted: [18F]DCFPyL) to provide precise localization information to target disseminated tumor deposits in men presenting with rising PSA after prostatectomy and radiotherapy (maximal local therapies). Moreover, we will consequently treat all identified disease with image-guided stereotactic ablative radiotherapy (SABR), which has shown tantalizing results achieving excellent tumor eradication rates with minimal toxicities. This study is uniquely positioned to enable the discovery of new biomarkers and the correlation of prognostic tests (e.g. genomic signatures) from the initial prostatectomy specimen with the PET-MR/CT imaging results and curative-intent treatment outcomes.
The significance of the proposed work towards a measurable impact in PCa care is important to emphasize. The study team believes this novel curative-intent approach will transform lives, as opposed to therapies that transiently impact incurable disease stages. Herein, the focus is on patients at the earliest point of the disease spectrum of recurrent PCa after curative-intent treatments. Our hypothesis is that PSMA-targeted [18F]DCFPyL PET-MR/CT allows earlier detection and localization of defined metastatic targets in these patients, at a stage amenable to image-guided curative-intent therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Alejandro Berlin, MD
- Phone Number: 2126 416-946-4501
- Email: alejandro.berlin@rmp.uhn.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Recruiting
- Princess Margaret Cancer Centre
-
Principal Investigator:
- Alejandro Berlin, MD
-
Contact:
- Alejandro Berlin, MD
- Phone Number: 5813 416-946-4501
- Email: alejandro.berlin@rmp.uhn.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
- ECOG performance status of 0-2
- Absence of significant comorbidities rendering patient nor suitable for curative ablative approaches
- No history of non-skin malignancy
- Histological evidence of prostate adenocarcinoma on previous radical prostatectomy.
- No use of any form of hormonal therapy in the previous 12 months, or intention to start HT at time of enrollment.
- Normal serum testosterone level ascertained within 4-6 weeks of enrollment
- Absence of known metastatic disease
- Radiological studies without evidence of regional or distant metastases: CT abdomen-pelvis and bone scan within previous 3 months
- Able to lie supine at least 60 minutes to comply with imaging and treatment.
- Absence of impaired renal function (calculated GFR > 30mL/min)
- Absence of sickle cell disease or other hemoglobinopathies
- No other medical conditions deemed by the PI to make patient ineligible for PET/MR scanning or SABR
No contraindications to MRI:
- Subject must weigh <136kg (scanner weight limit)
- Subject must not have pacemakers, cerebral aneurysm clips, shrapnel injury, or implantable electronic devices not compatible with MRI
- Prior anaphylactic reaction to gadolinium
Rising PSA after maximal local therapies (radical prostatectomy and either adjuvant or salvage radiotherapy):
- Three documented PSA rises, at least 1 month apart from post radiotherapy.
- PSA value >0.1 and < 3 ng/mL, within 4-6 weeks of enrollment
- No use of any forms of ADT in the previous 12 months nor contemplated to be used at time of study enrollment. Salvage ADT to be started when PSA reaches a value of 6.0ng/ml or greater.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [18F] DCFPyL PET/MRI
[18F] DCFPyL PET/MRI scans for patients with recurrent disease after radical prostatectomy and adjuvant/salvage radiotherapy. Lesions identified through [18F] DCFPyL PET/MRI will be treated with stereotactic ablative radiotherapy (SABR) or surgery. |
PET/MRI imaging using the radiotracer, [18F]DCFPyL
SABR as treatment for lesions identified using [18F]DCFPyL PET/MRI
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine if [18F]DCFPyL PET-MR/CT can identify early oligometastatic disease in patients with a rising PSA and negative staging (CS and BS) after standard-of-care maximal local therapies.
Time Frame: 3 years
|
Endpoint: Detection rates and performance metrics of [18F]DCFPyL PET-MR/CT in the post-prostatectomy plus adjuvant/salvage RT setting.
|
3 years
|
To determine if treating PET-MR/CT identified lesions with curative-intent treatment (e.g. stereotactic body radiation therapy or surgery) associated with favorable preliminary measures of clinical performance.
Time Frame: 3 Years
|
|
3 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between PSA kinetics and PET imaging parameters
Time Frame: 6 months post SABR
|
To explore the correlation between PSA kinetics and PET imaging parameters (SUV, dynamic data, volumetric studies)
|
6 months post SABR
|
Correlate between tissue biomarker and distant disease
Time Frame: 3 years
|
To explore the correlation between tissue biomarkers from prostatectomy specimen (e.g.
genomic signatures) and [18F]DCFPyL PET/MR-detected distant disease
|
3 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
[18F]DCFPyL PET/MR and PET/CT comparison
Time Frame: 3 years
|
To determine concordance and compare performance between [18F]DCFPyL PET/MR and PET/CT
|
3 years
|
Concordance of PET-MR/CT finding and histological confirmation of metastatic foci.
Time Frame: 3 years
|
To determine the concordance of PET-MR/CT findings and histological confirmation of metastatic foci.
|
3 years
|
Biomarker correlates
Time Frame: 3 years
|
To explore blood, urine and tissue biomarker correlates of imaging features and radiotherapy tumour resposnse.
|
3 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Alejandro Berlin, MD, Princess Margaret Cancer Centre - University Health Network
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-5532
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post Prostatectomy
-
Mansoura UniversityCompleted
-
Yonsei UniversityCompletedTransurethral ProstatectomyKorea, Republic of
-
Levita MagneticsUnknown
-
Consorci Sanitari IntegralCompleted
-
Albert Einstein Healthcare NetworkTerminatedPost ProstatectomyUnited States
-
University of Vermont Medical CenterCompletedProstate Cancer | Post-ProstatectomyUnited States
-
University of MichiganTerminatedProstate Cancer | Post Prostatectomy IncontinenceUnited States
-
Vanderbilt University Medical CenterTerminatedLaparoscopy | Nephrectomy | Prostatectomy | RoboticsUnited States
-
Maasstad HospitalCompletedPatient Satisfaction | Prostatectomy | Morphine | Injections, SpinalNetherlands
-
Changhai HospitalUnknownNephrectomy | Robotic Surgical Procedures | ProstatectomyChina
Clinical Trials on [18F]DCFPyL PET/MRI scan
-
Lawson Health Research InstituteOntario Institute for Cancer ResearchCompleted
-
VA Greater Los Angeles Healthcare SystemLantheus Medical ImagingNot yet recruiting
-
Columbia UniversityActive, not recruitingProstatic NeoplasmsUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedProstate CancerUnited States
-
Lawson Health Research InstituteCancer Care Ontario; Centre for Probe Development and CommercializationRecruiting
-
British Columbia Cancer AgencyRecruitingProstatic Neoplasms | Prostate CancerCanada
-
Johns Hopkins UniversityCompletedKidney Cancer | Renal Cell CarcinomaUnited States
-
Grand River HospitalSt. Joseph's Healthcare HamiltonUnknownProstate CancerCanada
-
Sir Mortimer B. Davis - Jewish General HospitalCompletedProstate CancerCanada